HOME >> MEDICINE >> NEWS
Clinical study results using Aldagen's product to isolate cord blood stem cells presented at ASH

Durham, NC -- December 11, 2006 Aldagen, Inc. today announced the presentation of data from a clinical trial using its ALDESORT product to isolate stem cells from cord blood. The trial is being conducted by Joanne Kurtzberg, MD, the Duke University physician who pioneered the use of umbilical cord blood as a treatment for fatal childhood cancers and genetic diseases in 1993. Dr. Kurtzberg presented positive interim results of the study at the 48th Annual Meeting of the American Society of Hematology in Orlando, Florida.

About the Study
ALDESORT enriches a unique population of stem and progenitor cells from cord blood that contribute to neutrophil and platelet engraftment and to immune reconstitution following transplantation. The primary goal of the clinical study is to determine if transplanting these enriched cells is safe. The study will also indicate if transplanting these cell populations could result in accelerated engraftment and lead to more favorable clinical outcomes compared to a historical control group from the Cord Blood Transplantation Trial (COBLT) study, a multicenter Phase II study sponsored by the National Heart, Lung and Blood Institute. At the time of the interim analysis, eleven pediatric patients with cancer or genetic diseases were transplanted with unrelated donor umbilical cord blood and a supplement of cord cells isolated using ALDESORT. Overall survival at 180 days was 90.9%, compared to an overall survival at 180 days of 57% in COBLT study. The cumulative incidence of neutrophil engraftment by day 42 was 90.9% (p=0.001) and platelet engraftment by day 100 was 79.5% (p=0.003).

The findings of this study once again show the promise of transplanting stem cells from umbilical cord blood to treat children with resistant cancers and genetic diseases, said Dr. Kurtzberg. The infusion of cells enriched with ALDESORT has had no adverse effects and appears to improve the speed and efficacy of cord bloo
'"/>

Contact: Michelle Linn
linnmich@comcast.net
508-419-1555
Linnden Communications
11-Dec-2006


Page: 1 2

Related medicine news :

1. Clinical data suggest potential versatility of ALIMTA-based regimens in lung cancer
2. Susan G. Komen for the Cure and American Society of Clinical Oncology partner in national initiative
3. Clinical review -- A psychological approach to the management of irritable bowel syndrome
4. NHLBI Asthma Clinical Research Networks and ALA ACRC Network to present at ATS 2007
5. Clinical trial data for Perforomist Inhalation Solution presented at International ATS Conference
6. Clinical guidelines for blood conservation during cardiac procedures developed
7. Clinical trial data for Perforomist Inhalation Solution to be presented at ATS on May 20, 2007
8. Clinical trial coordinators need more financial conflict-of-interest training
9. Clinical studies evaluate potential treatments for mouth ulcers
10. NIH names Clinical Trial Units for the Microbicide Trials Network
11. Clinical Trials Units selected for newly restructured HIV/AIDS research networks

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:12/6/2016)... ... 06, 2016 , ... 'Tis the season for family, festivity, food and fun! ... the season when eating healthy, staying active, and taking medication and doing daily foot ... do. , "Shopping trips, parties and family gatherings can take their toll on ...
(Date:12/6/2016)... , ... December 06, 2016 , ... ... , the only authorized OSHA Training Institute Education Center headquartered in Northern California, ... program focused on providing occupational safety and health training to public sector employees. ...
(Date:12/5/2016)... ... December 05, 2016 , ... Edward Buckingham MD ... the arrival of the newest Sciton laser in January 2017. The Halo is ... non-ablative and ablative wavelengths for exceptional results. Outperforming more traditional lasers, the innovative ...
(Date:12/5/2016)... ... December 05, 2016 , ... Researchers at Johns Hopkins ... growing brains of young athletes. Over the course of three years, researchers will study ... mouth guards. The mouth guards, equipped with special sensors, will track the location and ...
(Date:12/5/2016)... ... December 05, 2016 , ... ... provide alerting technology to Central Illinois Health Information Exchange (CIHIE) using its ... funds as the sole sub-recipient participating with the Illinois Health Information Exchange ...
Breaking Medicine News(10 mins):
(Date:12/5/2016)... Dec. 5, 2016 Spain Glaucoma Surgery Devices ... report, "Spain Glaucoma Surgery Devices Market Outlook to 2022", ... Devices market. The report provides value, in millions of ... within market segements - Canaloplasty Micro Catheters and Glaucoma ... and distribution shares data for each of these market ...
(Date:12/5/2016)... Calif. , Dec. 5, 2016 Sangamo BioSciences, ... genome editing, announced the presentation of preclinical and manufacturing data ... at the 58 th Annual Meeting of the American ... Diego, CA , from December 3-6, 2016. ... of hemophilia A which we believe is highly competitive, and ...
(Date:12/5/2016)... 2016  Cornerstone Pharmaceuticals, Inc., a privately held, ... two Phase I trials evaluating its lead compound, ... meeting of the American Society of Hematology (ASH) ... The two datasets show encouraging efficacy and safety ... and T-cell non-Hodgkin,s lymphoma (T-cell NHL), respectively, supporting ...
Breaking Medicine Technology:
Cached News: